These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 10098742)
1. Inhibition of transforming growth factor alpha (TGF-alpha)-mediated growth effects in ovarian cancer cell lines by a tyrosine kinase inhibitor ZM 252868. Simpson BJ; Bartlett JM; Macleod KG; Rabiasz G; Miller EP; Rae AL; Gordge P; Leake RE; Miller WR; Smyth J; Langdon SP Br J Cancer; 1999 Mar; 79(7-8):1098-103. PubMed ID: 10098742 [TBL] [Abstract][Full Text] [Related]
2. ErbB kinases and NDF signaling in human prostate cancer cells. Grasso AW; Wen D; Miller CM; Rhim JS; Pretlow TG; Kung HJ Oncogene; 1997 Nov; 15(22):2705-16. PubMed ID: 9400997 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor. Reddy KB; Mangold GL; Tandon AK; Yoneda T; Mundy GR; Zilberstein A; Osborne CK Cancer Res; 1992 Jul; 52(13):3636-41. PubMed ID: 1617636 [TBL] [Abstract][Full Text] [Related]
4. Pretreatment with vitamin A inhibits transforming growth factor alpha stimulation of human mammary carcinoma cells. Halter SA; Winnier AR; Arteaga CL J Cell Physiol; 1993 Jul; 156(1):80-7. PubMed ID: 7686167 [TBL] [Abstract][Full Text] [Related]
5. Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family. Bishop PC; Myers T; Robey R; Fry DW; Liu ET; Blagosklonny MV; Bates SE Oncogene; 2002 Jan; 21(1):119-27. PubMed ID: 11791182 [TBL] [Abstract][Full Text] [Related]
6. Multiple responses to EGF receptor activation and their abrogation by a specific EGF receptor tyrosine kinase inhibitor. Harper ME; Goddard L; Glynne-Jones E; Assender J; Dutkowski CM; Barrow D; Dewhurst OL; Wakeling AE; Nicholson RI Prostate; 2002 Jun; 52(1):59-68. PubMed ID: 11992620 [TBL] [Abstract][Full Text] [Related]
7. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. Bos M; Mendelsohn J; Kim YM; Albanell J; Fry DW; Baselga J Clin Cancer Res; 1997 Nov; 3(11):2099-106. PubMed ID: 9815602 [TBL] [Abstract][Full Text] [Related]
8. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Motoyama AB; Hynes NE; Lane HA Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928 [TBL] [Abstract][Full Text] [Related]
9. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Fan Z; Masui H; Altas I; Mendelsohn J Cancer Res; 1993 Sep; 53(18):4322-8. PubMed ID: 8364927 [TBL] [Abstract][Full Text] [Related]
10. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466 [TBL] [Abstract][Full Text] [Related]
11. Role of TGF alpha stimulation of the ERK, PI3 kinase and PLC gamma pathways in ovarian cancer growth and migration. Sewell JM; Smyth JF; Langdon SP Exp Cell Res; 2005 Mar; 304(1):305-16. PubMed ID: 15707595 [TBL] [Abstract][Full Text] [Related]
12. Protein kinase A-Ialpha subunit-directed antisense inhibition of ovarian cancer cell growth: crosstalk with tyrosine kinase signaling pathway. Alper O; Hacker NF; Cho-Chung YS Oncogene; 1999 Sep; 18(35):4999-5004. PubMed ID: 10490835 [TBL] [Abstract][Full Text] [Related]
13. Blockade of the epidermal growth factor receptor tyrosine kinase activity by quercetin and luteolin leads to growth inhibition and apoptosis of pancreatic tumor cells. Lee LT; Huang YT; Hwang JJ; Lee PP; Ke FC; Nair MP; Kanadaswam C; Lee MT Anticancer Res; 2002; 22(3):1615-27. PubMed ID: 12168845 [TBL] [Abstract][Full Text] [Related]
14. Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers. Maegawa M; Takeuchi K; Funakoshi E; Kawasaki K; Nishio K; Shimizu N; Ito F Mol Cancer Res; 2007 Apr; 5(4):393-401. PubMed ID: 17426253 [TBL] [Abstract][Full Text] [Related]
15. Reduced ability of transforming growth factor-alpha to induce EGF receptor heterodimerization and downregulation suggests a mechanism of oncogenic synergy with ErbB2. Gulliford TJ; Huang GC; Ouyang X; Epstein RJ Oncogene; 1997 Oct; 15(18):2219-23. PubMed ID: 9393980 [TBL] [Abstract][Full Text] [Related]
16. Significance of tyrosine kinase activity on malign transformation of ovarian tumors: a comparison between EGF-R and TGF-alpha. Zeren T; Inan S; Seda Vatansever H; Ekerbicer N; Sayhan S Acta Histochem; 2008; 110(3):256-63. PubMed ID: 18054376 [TBL] [Abstract][Full Text] [Related]